Eli Lilly and Company (LLY) Supplier List — 4 Verified Relationships
Eli Lilly and Company's supply chain includes active pharmaceutical ingredient (API) suppliers, contract manufacturers, logistics partners, and clinical research organizations named in annual and quarterly filings.
Eli Lilly and Company Suppliers (4 relationships from SEC filings)
The following suppliers are named in Eli Lilly and Company's SEC regulatory filings. Each entry includes the relationship type, confidence score based on filing evidence, and a direct excerpt from the source filing. Confidence scores reflect the directness of the disclosure — "High" indicates the company is named explicitly as a supplier in the filing text.
| Ticker | Company | Relationship | Confidence | Filing Evidence |
|---|---|---|---|---|
| BOEHRINGER-INGELHEIM | Boehringer Ingelheim | Spend | High | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| CHUGAI-PHARMACEUTICAL-CO-LTD | Chugai Pharmaceutical Co., Ltd | Spend | High | Chugai receives tiered royalty payments on worldwide net sales ranging in percentages from mid single digits to low teens, which we recognize as cost of sales. |
| F-HOFFMANN-LA-ROCHE-LTD | F. Hoffmann-La Roche Ltd | Spend | High | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| GENENTECH-INC | Genentech, Inc. | Spend | High | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
Filing Evidence Highlights
These excerpts are taken directly from Eli Lilly and Company's SEC filings and cross-referenced against counterparty disclosures. Every relationship in ChainSifter traces back to a primary regulatory source.
"Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim."
— Eli Lilly and Company SEC filing, sourced via ChainSifter
"Chugai receives tiered royalty payments on worldwide net sales ranging in percentages from mid single digits to low teens, which we recognize as cost of sales."
— Eli Lilly and Company SEC filing, sourced via ChainSifter
"Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales."
— Eli Lilly and Company SEC filing, sourced via ChainSifter
About This Data
ChainSifter extracts supply chain relationships from public SEC regulatory filings — 10-K annual reports, 10-Q quarterly reports, and 8-K current reports filed with the SEC. The extraction pipeline identifies named suppliers, contract manufacturers, key customers, and distribution partners, then cross-references each disclosure against the counterparty's own filings to validate and strengthen confidence scores.
For Eli Lilly and Company, the 4 supplier relationships reflect disclosures spanning multiple filing years. Newer filings carry higher weight; discontinued relationships are flagged and removed from the active graph. The data does not represent Eli Lilly and Company's complete supplier universe — only relationships explicitly named in public filings are captured.
For the full interactive graph including risk scores, relationship timelines, and filing links, see the LLY supply chain page.
Get alerts when Eli Lilly and Company's supply chain changes
ChainSifter monitors new SEC filings and notifies you when LLY's supplier or customer relationships change — new vendors added, existing ones dropped, or concentration risks flagged.
View LLY Chain Page See PricingFrequently Asked Questions
How many suppliers does Eli Lilly and Company have?
ChainSifter has mapped 4 verified supplier relationships for LLY based on disclosures in SEC 10-K and 10-Q filings. The actual number of suppliers in Eli Lilly and Company's full supply chain is larger — these are the relationships explicitly named in regulatory filings.
Where does Eli Lilly and Company source its key components?
Based on SEC filing disclosures, Eli Lilly and Company sources from a combination of domestic and international suppliers. The specific vendors and relationship details are visible on the full LLY chain page.
How is ChainSifter's supply chain data verified?
Every relationship in ChainSifter is extracted from primary SEC regulatory filings — 10-K annual reports and 10-Q quarterly reports — filed by public companies. Each entry links to the source filing text. Data is cross-referenced across both the reporting company's filings and the counterparty's own disclosures.
Can I get alerts when Eli Lilly and Company's supply chain changes?
Yes. ChainSifter monitors new SEC filings and triggers alerts when new supplier or customer relationships are added or removed. Create a free account and set up alerts for LLY on the LLY chain page.
What is Eli Lilly and Company's supply chain risk profile?
Eli Lilly and Company's supply chain risk is assessed based on supplier concentration, geographic exposure, and disclosed dependencies in regulatory filings. View the risk score and detailed breakdown on the LLY supply chain page.
Related Supply Chain Pages
ChainSifter covers pharmaceuticals supply chain relationships across thousands of public companies. Explore related chains:
ChainSifter provides supply chain relationship data derived from public SEC regulatory filings for research and informational purposes only. This is not investment advice. Relationship data is sourced exclusively from publicly available company disclosures. Data accuracy depends on the quality and completeness of underlying filings. Last generated: 2026-09-25. See full disclaimer.